

Boehringer Ingelheim

BOVINE
RESPIRATORY
DISEASE IS A
RELENTLESS
HACKER




## The immune system: always under attack

#### HUSBANDRY RISK FACTORS PLAY A KEY ROLE

#### HOUSING'

External factors can have a negative impact on microbial load and clearance, such as:

- Humidity
- Temperature
- Air quality (NH<sub>3</sub>, dust)
- Air movement and ventilation
- Clean and dry beds



#### COLOSTRUM MANAGEMENT<sup>1,2</sup>

- Quality
- Quantity (10% bodyweight)
- Quickly (6 hours)
- Quietly
- sQueaky clean
- Failure of passive transfer (IgG rate <8-13 g/L) doubles the risk of bronchopneumonia

#### **NUTRITION**<sup>1</sup>

- Adequate amount
- Quality
- Twice daily feeding
- Adequate fibre
- Good weaning protocol
- First 2 months critical to get it right

# STRESS, TRANSPORT AND GROUPING<sup>1-5</sup>

- Corticosteroid levels are increased under stressful conditions, disrupting the immune system
- Handling animals increases stress
- Mixing of animals, especially of differing age groups
- Routine procedures such as disbudding and castration

Environmental threats are always present, opening the door to relentless pathogen attack

# Respiratory pathogens: ultimate hackers of the immune system

THE INITIAL ATTACK – AVOID SECURITY BY SUPPRESSING THE IMMUNE SYSTEM



Ubiquitous respirovirus that breaks through mucus barriers & replicates covertly in macrophages. **Destabiliser** enabling secondary bacterial infections.

#### AG AT CA

BVD<sup>7</sup>

Insidious, well-hidden & persistent pestivirus that targets leukocytes. Potent down-regulator of the immune system.

#### Mh

Bacterial destroyer waiting for the chance to act. Armed with leukocyte damaging toxin causing fibrinous and necrotising lobar pneumonia.

#### BR5V9,10


Readily mutating pneumovirus leading to transient immunity.

Solo operator that can inflict inflammation and necrotising bronchiolitis.

The final attack - shut down the system, destroy leukocytes and generate calf pneumonia

# Assess and upgrade the calf immune system

EVALUATE THE SYSTEM SECURITY - WHAT IS THE LEVEL OF PROTECTION?



SET UP THE REQUIRED **PROTECTION** 

Use the right antigens in the vaccination programme



**EXECUTE THE PREVENTION PROGRAMME** 

> Start vaccination at the right age

Administer the correct number of doses

**VALIDATE THE ACQUIRED LEVEL OF PROTECTION** 




Confirm that herd immunity improves

Reduce the risk of respiratory disease with a strong protection plan

## Upgrade calf immunity with state-of-the-art vaccine-ware

#### DESIGNED FOR TODAY'S BRD CHALLENGE:



#### BVD, BRSV, PI3

• Proven by challenge against recent European viral antigens<sup>11</sup>




#### Mh

- Protection against one of the main<sup>8</sup> bacterial causes of pneumonia in young calves
- Proven by challenge<sup>11</sup>

# DOUBLE ADJUVANT MATRIX FOR EFFICIENT STIMULATION OF THE IMMUNE SYSTEM

- Saponin-based adjuvants
   (Quil-A) able to stimulate
   comprehensive immunity<sup>12</sup>
- Aluminium hydroxide prolongs antigen presentation to extend and strengthen the immune response<sup>13</sup>





#### IN 2 DIFFERENT FORMULATIONS:



ACTIVELY IMMUNISING CATTLE AGAINST:

M. haemolytica\* A1

Respiratory
Syncytial Virus

Parainfluenza 3 Virus



ACTIVELY IMMUNISING CATTLE AGAINST:

M. haemolytica\* A1

Respiratory
Syncytial Virus

Parainfluenza 3 Virus

+ Bovine Viral
Diarrhoea Virus

#### Rapid onset of immunity Continuous protection 3 WEEKS AFTER PRIMARY COURSE<sup>14</sup> 6 MONTHS' PROTECTION FOR ALL PATHOGENS" DESIGN: BRSV, PI3, BVD, Mannheimia haemolytica DESIGN: BRSV, PI3, BVD, Mannheimia haemolytica Vaccinated: n = 6 • Control: n = 6 Vaccinated: n = 13 • Control: n = 13Expression of Expression of clinical symptoms clinical symptoms - 3 weeks ------ 3 weeks -----**V1** = 1st vaccination V2 = 2<sup>nd</sup> vaccination Mh = Mannheimia haemolytica **End** = End of challenge (1-2 weeks) **V2 V2 Onset of immunity Duration of immunity Viral End** Mh End Mh End Viral End **CHALLENGE CHALLENGE Necropsy** Necropsy **OOI** viral challenge **DOI** viral challenge **RESULTS** Difference in amount: amount: p<0.001 amount: p<0.001 amount: p<0.001 amount: p<0.001 amount: p<0.05 p<0.001 duration: p<0.001 duration: p=0.01 duration: p<0.001 duration: p<0.001 duration: p<0.001 Difference in duration: BRSV (log<sub>10</sub>TCID<sub>50</sub> — Controls (log<sub>10</sub>TCID<sub>5</sub> (log<sub>10</sub>TCID<sub>5,</sub> BRSV BVD $\bigcirc$ 0 3 4 5 6 7 8 9 10 11 12 13 14 0 3 4 5 6 7 8 9 10 11 12 13 14 0 3 4 5 6 7 8 9 10 11 12 13 14 0 3 4 5 6 7 8 9 10 11 12 13 14 0 3 4 5 6 7 8 9 10 11 12 13 14 0 3 4 5 6 7 8 9 10 11 12 13 14 Days after challenge (DO) Days after challenge (D0) Days after challenge (DO) Days after challenge (DO) Days after challenge (D0) Days after challenge (D0) Significant reduction in amount and duration of viral excretion at both time points<sup>11,14</sup> OOI bacterial challenge **DOI** bacterial challenge Number of animals with clinical symptoms Mean of lung 3

Significant reduction of clinical signs and lung lesions caused by Mh at both time points<sup>11,14</sup>

Days after challenge (DO)

Controls

Vaccinated

Controls

Days after challenge (JD)

Vaccinated

Challenged with recent strains using recent European viral isolates<sup>11</sup>

# Designed to encourage field use, BOVALTO hardware delivers with ease and efficiency

#### A CONVENIENT AND RELIABLE VACCINATION PROGRAM



- Use from 2 weeks of age\*11
- Rapid onset of immunity 3 weeks post-primary course<sup>14</sup>
- 6 months' continuous protection<sup>11</sup>





- Targets the key respiratory pathogens in a single vial
- Ready-to-use for practical handling
- Small injection volume to reduce discomfort to calves

1st INJECTION DAY O

2<sup>nd</sup> INJECTION **3 WEEKS** 

**DURATION OF IMMUNITY** 6 MONTHS AFTER 2<sup>nd</sup> INJECTION INJECTION

**BOOSTER** 

**ONSET OF IMMUNITY** 3 WEEKS AFTER 2<sup>nd</sup> INJECTION



<sup>\*</sup>For calves from immune dams or where the immune status of the dam is unknown, the vaccination scheme should be adapted at the discretion of the veterinarian to take into account potential interference of maternally derived antibodies with the response to vaccination.

BOEHRINGER INGELHEIM IS COMMITTED TO SUPPORTING YOU IN DISEASE PREVENTION

# #CALFMATTERS

Visit calfmatters.co.uk for further information about how Boehringer can support you to protect the health of your clients' youngstock

#### **References:**

- 1. Foucras G *et al.* (2011) Bull GTV 61: 73-80
- 2. Boulton A et al. (2015) Open Journal of Animal Sciences 5: 185-197
- 3. Grignard L et al. (2001) Applied Animal Behaviour Science 71: 263-276
- 4. Maunsell FP *et al.* (2001) Applied Animal Behaviour Science 71, 203-27, 4. Maunsell FP *et al.* (2011) Journal of Animal Science 25(4): 772-783
- 5. Grupta S *et al.* (2005) Journal of Animal Science 85: 1948–1958
- 6. Ellis JA et al. (2010) Vet Clin Food Anim 26: 575-593
- 7. Lanyon SR et al. (2013) The Veterinary Journal 199: 201-209

- 8. Rice A et al. (2008) Animal Health Research Reviews 8(2): 117-128
- 9. Meyer G et al. (2008) Comp Immunol Microbiol Infect Dis. 31: 191-225
- 10. Baker JC *et al.* (1997) Vet Clin Food Anim 13(3): 425-454
- 11. Phillippe-Reversat et al. (2017) Acta Vet. BRNO 86: 325-332
- 12. O'Hagan D et al. (2001) Biomolecular Engineering 18: 69-85
- 13. Awate S *et al.* (2013) Frontiers in Immunology 4(114): 1-4
- 14. BOVALTO Respi 3 and 4, registration studies. Data on file.



BOVALTO® Respi 3 Suspension for Injection and BOVALTO® Respi 4 Suspension for Injection contain inactivated bovine respiratory syncytial virus, strain BIO-24, inactivated bovine parainfluenza 3 virus, strain BIO-23 and inactivated Mannheimia haemolytica, serotype A1 strain DSM 5283. BOVALTO Respi 4 also contains inactivated bovine viral diarrhoea virus, strain BIO-25. UK: POM-V IE: POM (E). Further information available in the SPCs or from Boehringer Animal Health UK Ltd, RG12 8YS, UK. UK Tel: 01344 746959 (sales) or 01344 746957 (technical), IE Tel: 01 291 3985 (all queries). Bovalto and the steerhead logo are registered trademarks of the Boehringer Ingelheim Group. ©2018 Boehringer Ingelheim Animal Health UK Ltd. All rights reserved. Date of preparation: Jun 2019. AHD12528. Use Medicines Responsibly.